An evaluation of the investigational drug GDC-0980 in patients with metastatic kidney cancer who have already received up to three therapies, with the approved drug everolimus as a comparison

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-000493-56

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

•To evaluate the efficacy of GDC-0980 versus everolimus as measured by progression-free survival (PFS) defined as the time from randomization to disease progression


Critère d'inclusion

  • Metastatic Renal Cell Carcinoma